To estimate the financial impact to the Ontario Public Drug Programs (OPDP) for providing coverage for methylnaltrexone subcutaneous injection (RELISTOR TM ) for the treatment of Opioid Induced Constipation (OIC) in patients with advanced illness, receiving palliative care when response to laxatives has been insufficient. METHODS: A population-based model was developed to estimate the annual financial impact of adding methylnaltrexone to the OPDP drug formulary. Attrition factors were applied in a stepwise approach starting with the population of Ontario in order to forecast the number of palliative patients expected to use methylnaltrexone following its addition to the drug formulary. Targeted treatment population in the analysis is limited to patients meeting the product monograph indication/criteria. Only drug costs incurred by the OPDP are included. No discounting or inflation were applied. Data sources included literature sources, publicly available population statistics, and market research. RESULTS: This analysis estimates that funding methylnaltrexone, per product monograph indication, in the province of Ontario would lead to an incremental drug reimbursement cost of $1, 754,265, $3,942,857, and $5,563,842 in Year 1, 2, and 3 respectively post listing. The total cumulative impact, post listing over the three-year period is expected to be $11.26 million. Pessimistic and optimistic scenarios were evaluated in the sensitivity analysis to provide a range of costs to the drug plan budget. The estimated impact over a three-year period will be an incremental cost of $6.65 million and $17.46 million for pessimistic and optimistic scenario respectively. CONCLU-SIONS: Addition of methylnaltrexone will provide patients and care providers with a therapeutic option to rapidly and reliably improve patient well-being at the end-of-life while having a modest impact on the OPDP drug budget. 
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METHODS:
The analytic model is based on data from disease prevalence, population growth, drug consumption, ex-factory prices and market shares forecasts for the Spanish market. It takes the perspective of the Spanish National Health Care System and time horizon considered is 5 years (annual discount rate at 5%). Drugs considered in the study were intravenous proton-pump inhibitors (PPIs): omeprazole, esomeprazole and pantoprazole. The model estimates the annual cost to treat patients with PU before and after of increased pantoprazol IV prescription. Annual costs includes pharmacologic treatment, laboratory and diagnostic tests, specialist consultation, hospitalization and other resources like transfusions, endoscopic treatments and surgery interventions. Health care resource consumption and unit costs have been obtained from a retrospective observational study that evaluated the re-bleeding prevalence by PU in patients treated with intravenous PPIs. All costs are referred to year 2007. RESULTS: Target population with peptic ulcer in Spain would be around 362,193 in year 2007, arriving at 378,048 in 2012 due to increase in Spanish population. Of these population it has been estimated that 5092 patients in year 2007 would be treated with intravenous PIPs (5315 patients in year 2012). Direct medical costs for the next 5 years for PU was estimated at €78.5 million before the increased pantoprazole prescription and at €77 million after its increase. Mean cost per patient was estimated at 2,513€ before the increase the pantoprazole participation and at 2464 after its increase. CONCLUSIONS: This budget impact model estimates that an increased intravenous pantoprazole prescription for the treatment of PU in Spain is going to represent a net savings of €1.5 million in the Spanish Health Care System in the next five years. To estimate the economic impact for the health care system due to the substitution of intravenous omeprazole and intravenous esomeprazole by intravenous pantoprazole in the treatment of gastro oesophageal reflux disease in Spain. METHODS: A budget impact model was developed. The analytic model was based on data from disease prevalence, population growth, drug consumption, ex-factory prices and market shares forecasts for Spain. It takes the perspective of the Spanish National Health Care System and time horizon considered is five years. Annual discount rate was set at 5%. Proton-pump inhibitors (PPIs) are the drugs of choice for the treatment of gastro oesophageal reflux disease (GERD) and drugs considered in the study were omeprazole, esomeprazole and pantoprazole. The model estimates the annual cost to treat patients with GERD before and after the replacement by pantoprazol IV in the management of the disease in the Spanish setting. Annual costs consist of pharmacologic treatments, laboratory and diagnostic tests, specialist consultations, hospitalizations, transfusions, endoscopic treatments and surgical interventions. All costs are referred to 2007. RESULTS: It has been estimated that target population with PPIs treatments for GERD in Spain would be around 79,372 inhabitants in year 2007, arriving at 82,849 in 2012 due to Spanish population growth. Total cost for the next 5 years for the treatment of GERD with intravenous PIPs was estimated at €1224 million before the substitution and at €1200 million after the substitution. Mean cost per patient was estimated at €2513 before the replacement by intravenous pantoprazole and at €2464 after its substitution. CONCLUSIONS: This budget impact analysis estimates that increased pantoprazole intravenous prescription for the treatment of GERD in Spain is likely to represent a net savings of €24 millions in the Spanish National Health Care System in the next 5 years. 
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Several UK primary care organizations consider alginates to be interchangeable and differentiate products solely on costs; as such many have implemented alginate substitution programs. The aim of this study was to evaluate the validity of alginate substitution programs by conducting an economic evaluation of the costs and outcomes of the two leading prescribed alginates in the UK. METHODS: A decision-analytic model was constructed based on cohort of 3367 patients starting alginate monotherapy in primary care. Transition probabilities were derived from observed switching patterns during the observation period. The model was populated with previously reported health state utilities to derive quality-adjusted life years (QALYs). Costs were derived from treatment pathways examining 1st line of therapy / initial therapy, and subsequent therapies (eg, 2nd line, 3rd line, etc). Costs were calculated by summing all lines of treatment prescribed over one year including the costs of clinical consultations. The model calculated incremental cost-effectiveness between GA and Peptac after 2 lines and 5 lines of therapy. RESULTS: The average annual incremental cost difference between patients starting monotherapy GA and Peptac after 2-lines and 5-lines of therapy was £2.04 and £3.06, respectively. Disaggregation of costs indicated there was an increased proportion of a cost attributed to consultation visits for those starting on Peptac attributed to higher switching rates requiring a GP consultation. The incremental cost per quality adjusted life year for 2nd line and 5th line was £2887 and £5305 per QALY. In the sensitivity analysis the model was insensitive to changes in QoL scores attributed to failing therapy. The cost per QALY figures were moderately influenced by the duration of treatment failure before commencing 2nd line therapy. CONCLUSIONS: Based on aggregated costs of therapy and reduced switching rates Gaviscon Advance was cost-effective compared to Peptac. We suggest that all alginates are clinically not the same and that a broader range of costs and impact on patients should be taken into consideration when implementing therapeutic substitution programs.
PGI8 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTS WHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
Gibbons CJ 1 , Morris J 1 , O'Sullivan AK 2 1 Schering-Plough, Welwyn Garden City, UK, 2 i3 Innovus, Medford, MA, USA OBJECTIVES: Recent clinical trials have confirmed that hepatitis C patients who failed to attain a sustained virologic response (SVR) on interferon-based therapy (pegylated or nonpegylated) may still attain SVR if they are re-treated with pegylated interferon alfa 2b therapy in combination with ribavirin. On the basis of the international EPIC trial, a license has been granted for pegylated interferon alfa 2b and ribavirin to be used in this type of re-treatment. We developed a costeffectiveness for this retreatment paradigm in Scotland, as part of our manufacturer submission to the Scottish Medicines Consortium. METHODS: Local costs were sourced and outcomes data from the EPIC trial were applied. Utilities and disease progression parameters were sourced from widely published and well-established sources including the British HTA report on hepatitis C. Our base case cost-effectiveness model compared the retreatment with no retreatment-this comparison reflects the current available treatment options in Scotland. RESULTS: Our base case model found retreatment with pegylated interferon alfa 2b plus ribavirin to be a cost-effective therapy compared with no retreatment. The ICER was £11,389/QALY in the base case, however this cost-effectiveness measure varied strongly by the genotype of the virus patients are carrying as well as by the patient's prior experience on therapy (i.e. why they originally failed to attain SVR). Patients with less virulent strains of hepatitis C and whose prior treatment failed due to relapse or non-compliance represent the most cost-effective subgroup with ICERs below £9000/QALY. CONCLUSIONS: Aside from the differences in ICERs associated with the different sub-groups identified, ICERs remained below the costeffectiveness threshold in the most typical treatment scenarios suggesting that the therapy will be a cost-effective addition to the Scottish treatment system.
